Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Acromegaly is described in the packet's definition as an acquired disorder related to excessive production of growth hormone (GH), characterized by progressive somatic disfigurement, mainly involving the face and extremities, and by systemic manifestations. Synonyms recorded for the condition include growth hormone excess and somatotroph adenoma. The packet classifies its prevalence as uncommon, at 1-9 in 100,000, with Orphanet among the cited sources.
The packet does not list individual phenotype annotations for acromegaly. Its definition describes progressive somatic disfigurement mainly involving the face and extremities, together with systemic manifestations. Age of onset and the order or severity of features are not certified in this packet.
The definition characterizes acromegaly as acquired and related to excessive production of growth hormone. The packet lists no associated genes and no inheritance pattern, and it does not certify a more specific mechanism. The synonym somatotroph adenoma appears among the recorded names for the condition.
Diagnostic methods and criteria are not certified in this packet.
FDA records in the packet list the following products with active market status: paltusotine (Palsonify, approved 2025-09-25), octreotide products (Bynfezia Pen, Mycapssa, Sandostatin LAR Depot, and Sandostatin), pasireotide (Signifor and Signifor LAR), pegvisomant (Somavert), and arginine hydrochloride (R-Gene), for which the packet states no indication. Orphan drug records with approved status for acromegaly additionally name lanreotide (Somatuline Depot). Several other orphan-drug entries for acromegaly have designated or withdrawn status; these are not current approved options. Other management approaches are not certified in this packet.
28 trials found
Prognosis, natural history, and long-term outcomes are not certified in this packet.
ClinicalTrials.gov records in the packet show several studies related to acromegaly, mostly recruiting or not yet recruiting. Listed titles include a phase 3 study of Debio 4126 in participants previously treated with somatostatin analogs, a phase 2 study of MAR002, a phase 3 study of long-acting octreotide injection, and an observational study of octreotide subcutaneous depot. Other records address functioning pituitary tumours treated with proton beam therapy, familial isolated pituitary adenoma genetics, and anesthesia-related airway questions in people with acromegaly. A trial title indicates the agent or topic under study and does not establish an intervention's effect.
Data assembled from 5 of 12 sources · Last updated Nov 18, 2026, 8:42 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning acromegaly
Updated Oct 5, 2026
Marea Therapeutics has dosed the first patient in a Phase 2 clinical trial of MAR002 for acromegaly, following promising Phase 1 results showing deep IGF-1 suppression. This investigational therapy may allow for dosing every two weeks, improving upon the current daily injection standard.
Researchers have developed a long-acting allosteric antagonist targeting the growth hormone receptor for the treatment of acromegaly. This advancement could enhance treatment options for patients suffering from this rare endocrine disorder.
A cross-sectional study evaluates nurses' knowledge and awareness of acromegaly in a high-volume tertiary center. The findings may inform training programs to enhance care for patients with this rare disease.
A recent study demonstrates that calcaneal quantitative ultrasound parameters have a strong correlation with DXA measurements in patients with acromegaly. This finding could enhance diagnostic accuracy and monitoring for this rare disease.
AstraZeneca has discontinued development on four pipeline assets, including one for acromegaly, while advancing a bispecific antibody targeting the EGFR protein. This strategic shift reflects a focus on enhancing their cancer portfolio.